New therapeutic intervention for persons with adrenal tumours and mild autonomous cortisol secretion: the OSI-CORT study
Research theme
Women's metabolic health People involved
Women's Metabolic Health Theme Lead
Status: Ongoing
This experimental medicine study focuses on a novel therapeutic intervention for persons with adrenal tumours and mild autonomous cortisol secretion (MACS), which is an established driver of increased cardiometabolic risk. As part of the OSI-CORT study, persons with MACS will be treated with osilodrostat, an inhibitor of cortisol biosynthesis.
Project aims
We will assess how osilodrostat affects steroid metabolism and the cortisol excess in MACS and – in turn – how this impacts glucose metabolism, muscle function, immune function, and global metabolism of persons living with this condition. The study will begin recruitment in 2024 and is due to complete before the end of the year.
Research projects
A database to improve maternal safety: Safe-Mums
We are in the process of establishing the Safe-Mum database on maternity datasets…
Predicting complications in gestational diabetes
We are in the process of establishing a living database on maternity datasets…
1PCOS database
We are in the process of establishing a living database on polycystic ovary…
